Long-term denosumab therapy led to improved BMD among patients with RDs, regardless of GC usage or renal function.

Rapid RTX infusion protocols appear to be a safe option for patients with autoimmune rheumatic diseases, potentially reducing the time spent in infusion clinics.

The FDA has approved Tonmya (cyclobenzaprine hydrochloride sublingual tablets) for the treatment of fibromyalgia in adults.

The Food and Drug Administration has granted Fast Track designation to CELZ-201-DDT for the treatment of degenerative disc disease.

High continuous metabolic syndrome severity score trajectory pattern was linked to increased risk for CKD in adjusted analyses.

GLP-1 RA injectable use prevalence among adults with diabetes was 26.5% in 2024, but rates were higher in some age and racial groups.

Complete or partial renal response and lupus low disease activity state were associated with lupus nephritis relapse risk reduction.